A growing body of research into Parkinson’s disease is challenging the assumption that the condition looks the same in every patient. Multiple large-scale studies now show that biological sex shapes not only which symptoms appear first but also how quickly they progress and how the brain responds at a molecular level. The findings carry direct consequences for diagnosis, treatment planning, and clinical trial design, because a one-size-fits-all approach may be leaving millions of patients with care that does not match their actual symptom profile.
Motor and Non-Motor Gaps Emerge Early
One of the clearest signals comes from the LS-1 cohort, a multi-site clinical-trial analysis of 1,741 people with early treated Parkinson’s. That study established which symptom domains differed by sex soon after treatment began, finding that motor features diverged from selected cognitive and non-motor measures in ways that depended on whether the patient was male or female. The data suggested that while gross motor scores at diagnosis can look similar across sexes, the non-motor picture, including mood, sleep, and autonomic function, already starts to split.
Separate research drawing on the Fox Insight platform, which collects patient-reported outcomes at scale, reinforced that split. Investigators quantified sex differences in symptom questionnaires and tested whether those gaps widened as the disease progressed. The results pointed to meaningful sex-by-disease-duration interactions, meaning that the longer a person lives with Parkinson’s, the more their symptom trajectory may diverge from someone of the opposite sex who received the same diagnosis at the same stage. In practice, this can translate into different combinations of fatigue, sleep disturbance, pain, and mood changes that evolve along distinct timelines for men and women.
Cognitive Decline Does Not Follow One Path
Beyond tremor and rigidity, cognitive decline is one of the most feared aspects of Parkinson’s. Research published in npj Parkinson’s Disease examined how cognitive performance varies by sex, tracking scores across distinct domains over time. The study found that sex relates to both the speed and the pattern of cognitive impairment, with certain domains, such as executive function, visuospatial skills, and verbal memory, showing different vulnerability depending on whether the patient is male or female.
This matters for patients and families because cognitive screening tools used in routine neurology visits often treat all scores against a single benchmark. If men and women decline along different cognitive axes, a standard cutoff could miss early warning signs in one group while over-flagging another. Clinicians who adjust their screening approach based on sex-specific trajectories could catch problems sooner and intervene earlier with targeted therapies, cognitive rehabilitation, or lifestyle changes tailored to the domains most likely to deteriorate.
Biological Pathways Offer a Molecular Explanation
Clinical observations alone do not explain why these differences exist. A biomarker-focused study in npj Parkinson’s Disease identified sex-linked patterns in the kynurenine pathway associated with symptom severity. The kynurenine pathway is a metabolic route for the amino acid tryptophan, and its byproducts can be either neuroprotective or neurotoxic. The researchers connected clinical differences to measurable alterations in plasma and cerebrospinal fluid across multiple cohorts, providing a biological mechanism rather than just a statistical association.
These findings dovetail with broader work on non-motor features, where investigators have reported that significant sex differences appear across many symptom domains, from depression and anxiety to sleep and autonomic dysfunction. Together, the molecular data and the clinical profiles suggest that sex hormones, immune responses, and metabolic pathways may interact to create distinct disease biology in men and women, rather than simply modifying the same underlying process.
Environmental Exposure Adds Another Layer
Biology is only part of the story. Environmental and occupational exposures can shape who develops Parkinson’s and how it manifests. Large cohort analyses have highlighted the role of pesticides, solvents, and other neurotoxicants, with one high-profile report noting that more than a third of participants reported pesticide contact linked to elevated risk. Because men and women often have different job histories, household roles, and residential patterns, their exposure profiles can diverge substantially.
That divergence may interact with sex-specific biology to influence not only who is diagnosed but which symptoms dominate. For example, long-term agricultural work, industrial jobs, or certain cleaning tasks may be more common in one sex within a given region, altering cumulative exposure to chemicals that damage dopaminergic neurons or other brain circuits. When layered on top of hormonal and genetic differences, this can help explain why some symptom clusters, such as axial motor problems or sleep disturbances, appear earlier or more severely in one sex.
Why Standard Care Falls Short
A narrative review published in late 2024 pulled together evidence on sex differences in epidemiology, clinical features, and therapeutic responses, and underscored gaps in how non-motor symptoms are managed. The authors concluded that current practice often fails to recognize sex-specific needs, resulting in underdiagnosis of certain problems and inconsistent access to multidisciplinary care. They argued that neurologists should routinely ask about non-motor issues and consider how sex might influence both symptom burden and treatment response.
Earlier work by Martinez-Martin and colleagues had already shown that some non-motor complaints are more frequent in women, including pain, fatigue, and mood disturbances. Yet clinical guidelines have been slow to reflect that evidence, and many treatment algorithms still implicitly assume a male “default” patient. A more recent synthesis of observational studies further noted that men and women with Parkinson’s experience measurable disparities in care, from differences in medication side effects to unequal access to advanced therapies such as deep brain stimulation.
Much of the gap traces back to how trials have been designed and how evidence has been translated into practice. Many pivotal studies of dopaminergic medications, device-based therapies, and rehabilitation strategies either under-enrolled women or did not analyze outcomes separately by sex. As a result, dosing recommendations, side-effect profiles, and expectations about benefit often reflect an average that may not match either group particularly well. When clinicians then apply these averages to individual patients without considering sex, they risk both under-treating symptoms and exposing people to avoidable adverse effects.
Implications for Diagnosis and Treatment
Recognizing sex differences in Parkinson’s is not about creating entirely separate care pathways for men and women. Instead, it means incorporating sex as a routine variable in clinical decision-making. For diagnosis, this could involve placing greater weight on non-motor complaints that tend to be more prominent in women, such as anxiety, pain, or sleep disruption, even when motor signs are subtle. For men, clinicians might pay closer attention to early cognitive changes or impulse-control behaviors that can be masked by a focus on tremor and rigidity.
In treatment planning, sex-specific patterns could inform medication choices and dosing strategies, particularly where pharmacokinetics and side-effect risks differ. Rehabilitation programs might be tailored to address the domains (motor, cognitive, or autonomic) that are most likely to deteriorate in each sex over time. Importantly, clinical trials should prospectively stratify by sex, ensure balanced enrollment, and report outcomes separately, so that future guidelines rest on evidence that reflects the full diversity of the Parkinson’s population.
For patients and caregivers, the emerging science offers a more nuanced and validating explanation for why two people with the same diagnosis can have such different journeys. It underscores the importance of describing all symptoms, not just the classic motor signs, and of advocating for care that recognizes how sex, environment, and biology intersect. As researchers continue to map these differences at the molecular, clinical, and societal levels, the hope is that Parkinson’s care will shift from a one-size-fits-all model to one that is genuinely personalized, starting with the fundamental distinction of sex.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
